ArticleScientific reports2026
Serum sialic acid binding immunoglobulin-like lectin-1 (sSIGLEC-1) in Egyptian patients with lupus nephritis: correlation with renal activity in non-European ancestry.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum sialic acid binding immunoglobulin-like lectin-1 (sSIGLEC-1) is a type I interferon-associated biomarker previously linked to lupus nephritis (LN) in European ancestry populations, but its utility in non-European cohorts remains poorly defined. This study aimed to validate the association of sSIGLEC-1 with LN in Egyptian SLE patients (non-European ancestry) and to test its correlation with world health organization (WHO) pathological classes, chronic kidney disease (CKD) stages, systemic lupus international collaborating clinics-renal activity score (SLICC-RAS), systemic lupus erythematosus disease activity index (SLEDAI), 24-hour urinary protein and proinflammatory cytokines. This cross-sectional study included 80 SLE patients (47 with LN, 33 without LN) and 20 healthy controls. Renal biopsy was classified according to WHO criteria. Estimated glomerular filtration rate (eGFR) and CKD stages were calculated. Median levels of sSIGLEC-1 were significantly higher in SLE patients than controls (113.5 vs. 11.2 pg/mL) and in LN patients than non-LN patients (117.7 vs. 110.0 pg/mL). Multivariable logistic regression confirmed sSIGLEC-1 as an independent predictor of LN (OR = 1.02, p = 0.04). sSIGLEC-1 correlated positively with SLEDAI (r = 0.26), SLICC-RAS (r = 0.31), and proinflammatory cytokines (IL-1β, IL-6, TNF-α), but did not correlate with 24-hour urinary protein (r = - 0.175). However, no significant differences in sSIGLEC-1 were observed across WHO pathological classes or CKD stages. ROC analysis showed poor discriminative ability for LN (AUC = 0.6928, sensitivity 93.6%, specificity 39.4%). In Egyptian SLE patients, sSIGLEC-1 is elevated in LN and correlates with disease activity but does not reflect histological severity or chronic kidney damage. Its low specificity limits diagnostic utility; however, high sensitivity suggests potential as a rule-out screening test for LN in non-European populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.